Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, has announced the completion of the acquisition of Bako Diagnostics, a premier pathology laboratory, and StrataDx, a premier dermatopathology laboratory, as previously announced on December 22, 2025. Under the terms of the agreement, Fulgent acquired certain assets of Bako Diagnostics and acquired StrataDx for a total combined purchase price of approximately $56.9 million in cash, subject to certain post-closing adjustments.
Read the full article: Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx //
Source: https://www.businesswire.com/news/home/20260317221536/en/Fulgent-Genetics-Completes-Acquisition-of-Bako-Diagnostics-and-StrataDx